$21.04
+1.2%Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Last Annual Value
209.61M
3-Year CAGR
23%
5-Year CAGR
34%
10-Year CAGR
23%
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Doximity, Inc. NYSE:DOCS | 209.61M | 22.9% | 34.0% | N/A | |
![]() Exact Sciences Corporation NASDAQ:EXAS | 606.64M | 35.7% | -16.5% | 30.9% | |
![]() Guardant Health, Inc. NASDAQ:GH | 629.75M | 64.3% | -5.4% | 64.8% | |
![]() HealthEquity, Inc. NASDAQ:HQY | 295.95M | 9.5% | 9.1% | 10.3% | |
![]() Viatris Inc. NASDAQ:VTRS | 736.10M | -16.5% | -2.8% | -5.1% | |
![]() Solventum Corporation NYSE:SOLV | 762.00M | 132.0% | 43.8% | N/A | |
![]() Encompass Health Corporation NYSE:EHC | 123.10M | 32.1% | -16.9% | 7.2% | |
![]() The Cooper Companies, Inc. NASDAQ:COO | 107.70M | -8.1% | -1.6% | 20.7% | |
![]() Revvity, Inc. NYSE:RVTY | 1.16B | 35.2% | 23.7% | 17.2% | |
![]() Tempus AI, Inc. NASDAQ:TEM | 340.95M | 3.9% | -7.9% | N/A |
Continue your DOCS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.